130 related articles for article (PubMed ID: 11158726)
1. Preclinical safety evaluation of avasimibe in beagle dogs: an ACAT inhibitor with minimal adrenal effects.
Robertson DG; Breider MA; Milad MA
Toxicol Sci; 2001 Feb; 59(2):324-34. PubMed ID: 11158726
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of the ACAT inhibitor avasimibe (CI-1011).
Llaverías G; Laguna JC; Alegret M
Cardiovasc Drug Rev; 2003; 21(1):33-50. PubMed ID: 12595916
[TBL] [Abstract][Full Text] [Related]
3. Hepatic and adrenal toxicity of a novel lipid regulator in beagle dogs.
Wolfgang GH; Robertson DG; Welty DF; Metz AL
Fundam Appl Toxicol; 1995 Jul; 26(2):272-81. PubMed ID: 7589916
[TBL] [Abstract][Full Text] [Related]
4. Subacute toxicity of a novel inhibitor of acyl-CoA: cholesterol acyltransferase in beagle dogs.
Dominick MA; McGuire EJ; Reindel JF; Bobrowski WF; Bocan TM; Gough AW
Fundam Appl Toxicol; 1993 Feb; 20(2):217-24. PubMed ID: 8383621
[TBL] [Abstract][Full Text] [Related]
5. Acyl-coenzyme A:cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7alpha-hydroxylase in cultured rat hepatocytes and in vivo in the rat.
Post SM; Zoeteweij JP; Bos MH; de Wit EC; Havinga R; Kuipers F; Princen HM
Hepatology; 1999 Aug; 30(2):491-500. PubMed ID: 10421659
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia.
Insull W; Koren M; Davignon J; Sprecher D; Schrott H; Keilson LM; Brown AS; Dujovne CA; Davidson MH; McLain R; Heinonen T
Atherosclerosis; 2001 Jul; 157(1):137-44. PubMed ID: 11427213
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
J Lipid Res; 1999 Jul; 40(7):1317-27. PubMed ID: 10393217
[TBL] [Abstract][Full Text] [Related]
8. The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs.
Burnett JR; Telford DE; Barrett PH; Huff MW
Biochim Biophys Acta; 2005 Dec; 1738(1-3):10-8. PubMed ID: 16427354
[TBL] [Abstract][Full Text] [Related]
9. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.
Raal FJ; Marais AD; Klepack E; Lovalvo J; McLain R; Heinonen T
Atherosclerosis; 2003 Dec; 171(2):273-9. PubMed ID: 14644397
[TBL] [Abstract][Full Text] [Related]
10. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits.
Bocan TM; Krause BR; Rosebury WS; Mueller SB; Lu X; Dagle C; Major T; Lathia C; Lee H
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):70-9. PubMed ID: 10634802
[TBL] [Abstract][Full Text] [Related]
11. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions.
Tardif JC; Grégoire J; L'Allier PL; Anderson TJ; Bertrand O; Reeves F; Title LM; Alfonso F; Schampaert E; Hassan A; McLain R; Pressler ML; Ibrahim R; Lespérance J; Blue J; Heinonen T; Rodés-Cabau J;
Circulation; 2004 Nov; 110(21):3372-7. PubMed ID: 15533865
[TBL] [Abstract][Full Text] [Related]
12. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice.
Delsing DJ; Offerman EH; van Duyvenvoorde W; van Der Boom H; de Wit EC; Gijbels MJ; van Der Laarse A; Jukema JW; Havekes LM; Princen HM
Circulation; 2001 Apr; 103(13):1778-86. PubMed ID: 11282910
[TBL] [Abstract][Full Text] [Related]
13. alpha-Substituted malonester amides: tools to define the relationship between ACAT inhibition and adrenal toxicity.
Sliskovic DR; Picard JA; O'Brien PM; Liao P; Roark WH; Roth BD; Anderson MA; Mueller SB; Bocan TM; Bousley RF; Hamelehle KL; Homan R; Reindel JF; Stanfield RL; Turluck D; Krause BR
J Med Chem; 1998 Feb; 41(5):682-90. PubMed ID: 9513596
[TBL] [Abstract][Full Text] [Related]
14. Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor.
Taghibiglou C; Van Iderstine SC; Kulinski A; Rudy D; Adeli K
Biochem Pharmacol; 2002 Feb; 63(3):349-60. PubMed ID: 11853686
[TBL] [Abstract][Full Text] [Related]
15. Hepatic microsomal induction profile of carbamic acid [[2,6-bis(1- methylethyl)phenoxy] sulfonyl]-2,6-bis(1-methylethyl) phenyl ester, monosodium salt (PD138142-15), a novel lipid regulating agent.
Robertson DG; Krause BR; Welty DF; Wolfgang GH; Graziano MJ; Pilcher GD; Urda E
Biochem Pharmacol; 1995 Mar; 49(6):799-808. PubMed ID: 7702638
[TBL] [Abstract][Full Text] [Related]
16. Effects of compound X, a novel potent inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase, on the adrenal gland of rats.
Nishimura J; Ohmichi K; Wato E; Saito T; Takashima K; Tanaka T; Hiwatashi Y; Kobayashi K; Tsujimoto T; Asahiyama M; Itagaki K; Tanabe S; Kato N; Amano Y
Exp Toxicol Pathol; 2013 Nov; 65(7-8):961-71. PubMed ID: 23462190
[TBL] [Abstract][Full Text] [Related]
17. Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
Worthley SG; Helft G; Corti R; Worthley MI; Chew DP; Fayad ZA; Zaman AG; Fallon JT; Fuster V; Badimon JJ
Pathophysiol Haemost Thromb; 2007; 36(1):9-17. PubMed ID: 18332609
[TBL] [Abstract][Full Text] [Related]
18. Hypolipidemic and antioxidant activity of the novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor KY-455 in rabbits and hamsters.
Nakamura S; Kamiya S; Shirahase H; Kanda M; Yoshimi A; Tarumi T; Kurahashi K
Arzneimittelforschung; 2004; 54(2):102-8. PubMed ID: 15038459
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of acyl-coenzyme a: cholesterol acyltransferase.
Miyazaki A; Kanome T; Watanabe T
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):463-9. PubMed ID: 16503866
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of acyl-CoA:cholesterol O-acyltransferase. synthesis and pharmacological activity of (+/-)-2-dodecyl-alpha-phenyl-N-(2,4,6-trimethoxyphenyl)-2H-tetrazole-5- acetamide and structurally related tetrazole amide derivatives.
O'Brien PM; Sliskovic DR; Picard JA; Lee HT; Purchase CF; Roth BD; White AD; Anderson M; Mueller SB; Bocan T; Bousley R; Hamelehle KL; Homan R; Lee P; Krause BR; Reindel JF; Stanfield RL; Turluck D
J Med Chem; 1996 Jun; 39(12):2354-66. PubMed ID: 8691430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
